BioSpace News Archive

The global RNAi Technology Market is on a trajectory that will take the market worth up to an impressive figure by the end of the forecast period of 2018 to 2028, thanks to a steady growth rate, compounded annually, accelerating the growth momentum.

Highlighting Novel Antithrombotic Platform and Late-Stage Clinical Development Programs in Cancer, COVID-19 and Sickle Cell Disease

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease.

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 61,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted for oral presentation at the Charing Cross (CX) International Symposium taking place virtually April 19-22, 202

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter and year ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design

Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide’s treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference